Advanced Filter

Filter by Group

Filter by Market Availability

Displaying drugs 676 - 700 of 8722 in total
Constituent of striated muscle and liver. It is used therapeutically to stimulate gastric and pancreatic secretions and in the treatment of hyperlipoproteinemias.
Approved
Investigational
Matched Iupac: … (3R)-3-hydroxy-4-(trimethylazaniumyl)butanoate …
Matched Salts cas: … 220349-64-4
Acetylcarnitine is an investigational drug in the United states, Italy, United Kingdom, China, Israel, and Norway, and it is approved in Italy, Portugal, Argentina, Chile, Philippines, Australia, and India. Acetylcarnitine can be synthesized, but it is also naturally found in adequate amounts in healthy humans. In human plasma and tissues,...
Approved
Investigational
Matched Iupac: … (3R)-3-(acetyloxy)-4-(trimethylazaniumyl)butanoate …
A preparation of methionine that includes a mixture of D-methionine and L-methionine isomers.
Approved
Experimental
Matched Iupac: … 2-amino-4-(methylsulfanyl)butanoic acid …
Renal cell carcinoma (RCC) is responsible for 3% of cancer cases and is one of the 10 most common cancers in adults. The average age of diagnosis is between age 65 to 74. Tivozanib, also known as FOTIVDA, is a kinase inhibitor developed to treat adult patients with relapsed or...
Approved
Investigational
Matched Iupac: … 1-{2-chloro-4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-3-(5-methyl-1,2-oxazol-3-yl)urea …
Nonoxynol-9 (N-9) is a typical surfactant used as a vaginal spermicide. Spermicides are locally acting non-hormonal contraceptives. When present in the vagina during intercourse, they immobilize/inactivate/damage and/or kill sperms without eliciting systemic effects. N-9 has been in use for more than 30 years as an over-the-counter (OTC) drug in creams,...
Approved
Withdrawn
Matched Iupac: … 26-(4-nonylphenoxy)-3,6,9,12,15,18,21,24-octaoxahexacosan-1-ol …
Dabrafenib mesylate (Tafinlar) is a reversible ATP-competitive kinase inhibitor and targets the MAPK pathway. It was approved on May 29, 2013, for the treatment of melanoma with V600E or V6000K mutation. It was also used for metastatic non-small cell lung cancer with the same mutation. In May 2018, Tafinlar (dabrafenib),...
Approved
Investigational
Matched Iupac: … N-{3-[5-(2-aminopyrimidin-4-yl)-2-tert-butyl-1,3-thiazol-4-yl]-2-fluorophenyl}-2,6-difluorobenzene-1- …
Trypan blue is a diazo dye used in ophthalmic cataract surgery to stain the anterior capsule in the presence of a mature cataract. This is done to aid in visualization before creating the continuous curvilinear capsulorhexis.
Approved
Matched Iupac: … [1,1'-biphenyl]-4-yl}diazen-1-yl]-4-hydroxynaphthalene-2,7-disulfonic acid ... 5-amino-3-[(E)-2-{4'-[(E)-2-(8-amino-1-hydroxy-3,6-disulfonaphthalen-2-yl)diazen-1-yl]-3,3'-dimethyl- …
Bilastine is a novel new-generation antihistamine that is highly selective for the H1 histamine receptor, has a rapid onset and prolonged duration of action.
Approved
Investigational
Matched Iupac: … 2-[4-(2-{4-[1-(2-ethoxyethyl)-1H-1,3-benzodiazol-2-yl]piperidin-1-yl}ethyl)phenyl]-2-methylpropanoic …
Laropiprant is an ingredient in the EMA-withdrawn product Pelzont.
Approved
Investigational
Withdrawn
Matched Iupac: … 2-[(3R)-4-[(4-chlorophenyl)methyl]-7-fluoro-5-methanesulfonyl-1H,2H,3H,4H-cyclopenta[b]indol-3-yl]acetic …
Sibutramine (trade name Meridia in the USA, Reductil in Europe and other countries), usually as sibutramide hydrochloride monohydrate, is an orally administered agent for the treatment of obesity. It is a centrally acting stimulant chemically related to amphetamines thus it is classified as a Schedule IV controlled substance in the...
Approved
Illicit
Investigational
Withdrawn
Matched Iupac: … {1-[1-(4-chlorophenyl)cyclobutyl]-3-methylbutyl}dimethylamine …
Treosulfan is under investigation in Allogeneic Haematopoietic Stem Cell Transplantation. Treosulfan has been investigated for the treatment of Lymphoblastic Leukemia, Acute, Childhood.
Approved
Investigational
Matched Iupac: … (2S,3S)-2,3-dihydroxy-4-(methanesulfonyloxy)butyl methanesulfonate …
Fenpropidin has been investigated for the treatment of Hernia.
Approved
Experimental
Matched Iupac: … 1-{2-[(4-tert-butylphenyl)methyl]propyl}piperidine …
Apronalide is approved in Japan. Apronalide has been withdrawn from the market in many other countries due to patient development of thrombocytopenic purpura .
Approved
Matched Iupac: … [2-(propan-2-yl)pent-4-enoyl]urea …
Pimethixene is approved for use in Brazil and is marketed under the trade name Muricalm. It is an anticholinergic used in the treatment of bronchitis.
Approved
Matched Iupac: … 1-methyl-4-(9H-thioxanthen-9-ylidene)piperidine …
Benfotiamine has been investigated for the treatment and prevention of Diabetic Nephropathy and Diabetes Mellitus, Type 2.
Approved
Experimental
Matched Iupac: … {[(3Z)-4-{N-[(4-amino-2-methylpyrimidin-5-yl)methyl]formamido}-3-[(Z)-benzoylsulfanyl]pent-3-en-1-yl] …
Rupatadine is a dual histamine H1 receptor and platelet activating factor receptor antagonist that is used for symptomatic relief in seasonal and perennial rhinitis as well as chronic spontaneous urticaria. It was approved for marketing in Canada under the tradename Rupall and comes in tablet formulation for adult use and...
Approved
Matched Iupac: … 13-chloro-2-{1-[(5-methylpyridin-3-yl)methyl]piperidin-4-ylidene}-4-azatricyclo[9.4.0.0^{3,8}]pentadeca …
Approved
Matched Iupac: … 2-ethoxyethyl (2E)-3-(4-methoxyphenyl)prop-2-enoate …
Trilostane is an inhibitor of 3 beta-hydroxysteroid dehydrogenase used in the treatment of Cushing's syndrome. It was withdrawn from the United States market in April 1994.
Approved
Investigational
Vet approved
Withdrawn
Matched Iupac: … ene-4-carbonitrile ... 11S,12S,15S,16S)-5,15-dihydroxy-2,16-dimethyl-7-oxapentacyclo[9.7.0.0^{2,8}.0^{6,8}.0^{12,16}]octadec-4- …
Long-acting plasma-bound sulfonamide used for respiratory and urinary tract infections and also for malaria.
Approved
Withdrawn
Matched Iupac: … 4-amino-N-(3-methoxypyrazin-2-yl)benzene-1-sulfonamide …
Quinethazone, marketed as Hydromox, is a thiazide diuretic indicated for hypertension. Patients may experience adverse reactions such as dizziness, dry mouth, nausea, and hypokalemia.
Approved
Matched Iupac: … 7-chloro-2-ethyl-4-oxo-1,2,3,4-tetrahydroquinazoline-6-sulfonamide …
Long acting sulfonamide used in leprosy, urinary, and respiratory tract infections.
Approved
Matched Iupac: … 4-amino-N-(5-methoxypyrimidin-2-yl)benzene-1-sulfonamide …
Flosequinan was approved in the USA and the UK for a year prior to being withdrawn from the market due to increased mortality in chronic heart failure patients, found in drug trials.[A174979,L43942]
Approved
Withdrawn
Matched Iupac: … 7-fluoro-3-methanesulfinyl-1-methyl-1,4-dihydroquinolin-4-one …
Approved
Experimental
Matched Iupac: … 1-methoxy-4-[(1E)-prop-1-en-1-yl]benzene …
Alpha-dihydroergocryptine is usually referred to the mixture of the alpha and beta dihydroergocryptine. These two compounds are differentiated in the position of a methyl group. This structural difference is due to a proteinogenic amino acid replacement from leucine to isoleucine. Both compounds are hydrogenated ergot derivatives. Alpha-dihydroergocryptine approved drug product...
Approved
Matched Iupac: … -tetraene-4-carboxamide ... (2R,4R,7R)-N-[(1S,2S,4R,7S)-2-hydroxy-7-(2-methylpropyl)-5,8-dioxo-4-(propan-2-yl)-3-oxa-6,9-diazatricyclo ... [7.3.0.0^{2,6}]dodecan-4-yl]-6-methyl-6,11-diazatetracyclo[7.6.1.0^{2,7}.0^{12,16}]hexadeca-1(16),9,12,14 …
Sparsentan is a dual antagonist of the endothelin type A receptor (ETAR) and the angiotensin II (Ang II) type 1 receptor (AT1R) with a similar affinity for both (9.3 nM for ETAR and 0.8 nM for AT1R).[A257330,L45300] Sparsentan is first in its class and orally active, and was created by...
Approved
Investigational
Matched Iupac: … 4'-({2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl}methyl)-N-(4,5-dimethyl-1,2-oxazol-3-yl)-2'-(ethoxymethyl …
Displaying drugs 676 - 700 of 8722 in total